🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the battle against superbug strains of the pathogen, according to scientists.

A Worldwide Health Concern

Cases of gonorrhoea are increasing globally, with figures suggesting over 82 million infections each year. Particularly high rates are observed in Africa and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, escalating drug resistance and the extremely scarce treatment choices currently available.”

Medical experts are increasingly worried about the rise in drug-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Clearance

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is employed against urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a unique collaborative effort for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This milestone signifies a major breakthrough in the management of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Data and Worldwide Availability

According to results published in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This puts it on an comparable level with the current standard treatment, which uses an injection and a pill. The research included over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in a wide range of regions with limited resources.

Doctors on the front lines have voiced hope. Having a single-dose, oral treatment like this is seen as a "critical tool" for public health efforts. This is viewed as vital to alleviate the strain of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.